For instance, PPARγ agonists enhance pro-apoptotic pathways (e.g., p21 and Bax), suppressing osteosarcoma growth (209, 210), and improve therapeutic responses in high-risk NB by promoting differentiation and metabolic reprogramming (211, 212). Here, PPARG is linked to osteosarcoma.